News & Videos - NEOS THERAPEUTICS INC.

$100M revenue specialty pharmaceutical company on an accelerated path to profitability [1] Company name change to Aytu BioPharma, Inc. becomes effective today Former Neos Therapeutics board members Beth P. Hecht and Gerald McLaughlin have joined the Aytu BioPharma board of directors ENGLEWOOD, CO / ACCESSWIRE / March 22, 2021 / Aytu BioScience, Inc. (NASDAQ:AYTU), a specialty pharmaceutical company focused on commercializing novel therapeutics and consumer healthcare products, today announced...

...

Thinking about buying stock in Neos Therapeutics, Oriental Culture, Sino-Global Shipping, Bank of America, or Can Fite Biopharma? PR Newswire NEW YORK, March 18, 2021 NEW YORK , March 18, 2021 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for NEOS, OCG, SINO, BAC, and CANF. To see how InvestorsObserver's proprietary scoring system rates these stocks, view the InvestorsObserver's PriceWatch Alert by selecting the corresponding link. NEOS:...

...

- Record date for each Special Meeting of Stockholders is February 5, 2021 - - Upon merger closing, combined company will be renamed Aytu Biopharma, Inc. - ENGLEWOOD, CO and GRAND PRAIRIE, TX / ACCESSWIRE / February 10, 2021 / Aytu BioScience, Inc. (NASDAQ:AYTU), a specialty pharmaceutical company focused on commercializing novel products that address significant patient needs, and Neos Therapeutics, Inc. (NASDAQ:NEOS), a commercial-stage pharmaceutical company developing and manufacturing...

SHAREHOLDER ALERT: Monteverde & Associates PC Announces an Investigation of Neos Therapeutics, Inc. - NEOS PR Newswire NEW YORK, Jan. 28, 2021 NEW YORK , Jan. 28, 2021 /PRNewswire/ -- Juan Monteverde , founder and managing partner at Monteverde & Associates PC , a national securities firm rated Top 50 in the 2018 and 2019 ISS Securities Class Action Services Report and headquartered at the Empire State Building in New York City , is investigating Neos Therapeutics, Inc. ("NEOS" or the "Company")...

...

NEOS THERAPEUTICS INVESTOR ALERT BY THE FORMER ATTORNEY GENERAL OF LOUISIANA: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Neos Therapeutics, Inc. - NEOS PR Newswire NEW ORLEANS, Dec. 16, 2020 NEW ORLEANS , Dec. 16, 2020 /PRNewswire/ -- Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC ("KSF") are investigating the proposed sale of Neos Therapeutics, Inc. (NasdaqGS: NEOS) to Aytu BioScience, Inc....

ALERT: Rowley Law PLLC is Investigating Proposed Acquisition of Neos Therapeutics, Inc. PR Newswire NEW YORK, Dec. 10, 2020 NEW YORK , Dec. 10, 2020 /PRNewswire/ -- Rowley Law PLLC is investigating potential securities law violations by Neos Therapeutics, Inc. (NASDAQ: NEOS) and its board of directors concerning the proposed acquisition of the company by Aytu BioScience, Inc. (NASDAQ: AYTU). Stockholders will receive 0.1088 shares of Aytu BioScience common stock for each share of Neos...

...

SHAREHOLDER ALERT: WeissLaw LLP Investigates Neos Therapeutics, Inc. PR Newswire NEW YORK, Dec. 10, 2020 NEW YORK , Dec. 10, 2020 /PRNewswire/ -- WeissLaw LLP is investigating possible breaches of fiduciary duty and other violations of law by the board of directors of Neos Therapeutics, Inc. ("NEOS" or the "Company") (NASDAQ: NEOS) in connection with the proposed acquisition of the Company by Aytu BioScience, Inc. ("Aytu") (NASDAQ: AYTU). Under the terms of the merger agreement, NEOS...

Thinking about buying stock in Neos Therapeutics, Oncternal Therapeutics, Heat Biologics, FuelCell Energy, or Cinedigm Corp? PR Newswire NEW YORK, Dec. 10, 2020 NEW YORK , Dec. 10, 2020 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for NEOS, ONCT, HTBX, FCEL, and CIDM. To see how InvestorsObserver's proprietary scoring system rates these stocks, view the InvestorsObserver's PriceWatch Alert by selecting the corresponding link. NEOS:...

Merger accelerates transformation to profitability, with estimated annualized cost synergies of $15M beginning FY 2022 Aytu adds Neos' established, multi-brand ADHD portfolio, enhancing Aytu's footprint in pediatrics and expanding its presence in adjacent specialty care segments Opportunity to leverage and further enhance Neos RxConnect, a best-in-class patient support program, for Aytu's product portfolio of best-in-class prescription therapeutics and consumer health products Companies to host...

...

...

NEW YORK, NY / ACCESSWIRE / August 8, 2017 / Neos Therapeutics, Inc. (NASDAQ: NEOS ) will be discussing their earnings results in their Q2 Earnings Call to be held on Tuesday, August 8, 2017 at 8:30 AM Eastern Time. To listen to the event live - visit https://www.investornetwork.com/company/24586 . Replay Information The replay will be available online at https://www.investornetwork.com/company/24586 . About Investor Network Investor Network (IN) is a new financial content community, serving...

VIDEO FINANCIAL REPORTING Why invest in is the first financial video platform where you can easily search through thousands of videos describing global ......

DALLAS and FORT WORTH, Texas, Feb. 02, 2017 (GLOBE NEWSWIRE) -- Neos Therapeutics, Inc. (Nasdaq:NEOS), a pharmaceutical company focused on developing, manufacturing and commercializing innovative extended-release (XR) products using its proprietary modified-release drug delivery and orally disintegrating tablet (ODT) technology platforms, today announced that it has commenced an underwritten public offering of its common stock. In addition, Neos expects to grant the underwriters a 30-day option...

DALLAS/FORT WORTH, Texas, Dec. 20, 2016 (GLOBE NEWSWIRE) -- Neos Therapeutics, Inc. (NASDAQ:NEOS), a pharmaceutical company focused on developing, manufacturing and commercializing innovative extended-release (XR) products using its proprietary modified-release drug delivery and orally disintegrating tablet (ODT) technology platforms today announced that it has completed the resubmission of a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for Cotempla XR-ODT™, the...

DALLAS/FORT WORTH, Texas, Dec. 07, 2016 (GLOBE NEWSWIRE) -- Neos Therapeutics, Inc. (NASDAQ:NEOS), a pharmaceutical company focused on developing and commercializing innovative extended-release (XR) products for the treatment of attention-deficit/hyperactivity disorder (ADHD), today announced that Vipin Garg, Ph.D., president and chief executive officer, will participate in a fireside chat at the upcoming BMO Prescription for Success Healthcare Conference on Wednesday, December 14, 2016 at 9:00...